F9 and hemophilia B: The first drug utilizing the potential of genetic therapy for hemophilia B is etranacogene dezaparvovec, which contains a recombinant AAV serotype 5 vector targeted at liver cells and a codon-optimized variant of the human factor IX gene (Padua) (Anguela and High 2024).